A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis

Tofacitinib (CP-690550), an oral Janus kinase inhibitor, has shown significant efficacy in the treatment of rheumatoid arthritis through blocking the signaling pathways of pro-inflammatory cytokines. However, recent evidence suggests that long-term tofacitinib treatment is associated with increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yong, Gong, Fang-Yuan, Li, Zhen-Jun, Gong, Zheng, Zhou, Zhe, Ma, Shu-Yan, Gao, Xiao-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533717/
https://www.ncbi.nlm.nih.gov/pubmed/28754958
http://dx.doi.org/10.1038/s41598-017-07261-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533717/
https://www.ncbi.nlm.nih.gov/pubmed/28754958
http://dx.doi.org/10.1038/s41598-017-07261-1

Ejemplares similares